Myriad Teams with Topin to Market OnDose to Oncologists
May 25, 2011
Myriad Teams with Topin to Market OnDose to Oncologists
Topin will create a marketing strategy around OnDose, prepare marketing materials, and conduct meetings to educate oncologists about the pharmacokinetic test.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Saladax Regains Rights to My5-FU Assay from Myriad
February 11, 2013 / GenomeWeb Daily News - Myriad to Replace BRACAnalysis, Other Hereditary Cancer Tests with MyRisk Panel
May 9, 2013 / GenomeWeb Daily News - Myriad Partners with RainDance for Front End of NGS-based Hereditary Cancer Panel Test
April 17, 2013 / Clinical Sequencing News - Foundation Medicine to Develop Dx for Agios Cancer Therapeutics
April 4, 2013 / GenomeWeb Daily News - Myriad, PharmaMar Enter CDx Agreement for HRD Test
March 27, 2013 / GenomeWeb Daily News